Best Possible Medication History at USB (bpmh@USB)

May 5, 2020 updated by: University Hospital, Basel, Switzerland

Best Possible Medication History at Universitätsspital Basel (USB)

This pilot project investigates the use of a structured medication history (Best Possible Medication History, BPMH) in patients (primarily admitted at the emergency department of University Hospital Basel) after transfer to a medical ward. Unintentional medication discrepancies are analyzed comparing outpatient and inpatient medication therapy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

160

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
      • Basel, Switzerland, 4031
        • Spitalpharmazie Universitätsspital Basel (USB)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients admitted to Emergency Department of University Hospital Basel and being transfered to medical ward

Description

Inclusion Criteria:

  • Admission to Emergency Department of University Hospital Basel and transfer to medical ward

Exclusion Criteria:

  • medication history taken at Emergency Department of University Hospital Basel not present

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
unintended medication discrepancy
Time Frame: single time point (1 day after admission to hospital)
number of unintended medication discrepancies comparing medication history taken when admitted to emergency department and BPMH after transfer to medical ward
single time point (1 day after admission to hospital)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Categorisation ( Class1, Class2, Class3) for clinical relevance of unintended medication discrepancy
Time Frame: during 7 days after admission to hospital
expert panel classifies each unintended medication discrepancy in 1 of 3 classes for its potential to cause patient harm. Class 1 discrepancies are those unlikely to cause patient discomfort or clinical deterioration. Class 2 discrepancies could potentially result in moderate discomfort or clinical deterioration. Class 3 discrepancies could potentially result in severe discomfort or clinical deterioration.
during 7 days after admission to hospital

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Basel, Switzerland

Investigators

  • Principal Investigator: Stephan Gut, Spitalpharmazie Universitätsspital Basel (USB)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

September 1, 2017

Primary Completion (ACTUAL)

October 31, 2017

Study Completion (ACTUAL)

December 30, 2019

Study Registration Dates

First Submitted

February 12, 2019

First Submitted That Met QC Criteria

February 21, 2019

First Posted (ACTUAL)

February 22, 2019

Study Record Updates

Last Update Posted (ACTUAL)

May 6, 2020

Last Update Submitted That Met QC Criteria

May 5, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2017-00575; qu17Gut

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Best Possible Medication History

Clinical Trials on BPMH structured interview

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe